Cytokinetics, Incorporated

Historical 13F Holders

Symbol
CYTK
CUSIP
23282W605
All holders as of
Q2 2026
Type
Equity
Class
COM NEW
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 23282W605 since 12/18/2024, largest first.

Filer % of Class Filed
T. Rowe Price Investment Management, Inc. 13G/A 14.5% 2/17/2026
Event 12/31/2025
Vanguard Capital Management LLC 13G 5.2% 4/29/2026
Event 3/31/2026
State Street Corp 13G 5.1% 11/10/2026
Event 9/30/2026
Wellington Management Group LLP 13G/A
5.1% 8/13/2026
Event 6/30/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (2)
FMR LLC 13G/A
3.9% 7/8/2026
Event 6/30/2026
Vanguard Group Inc 13G/A 0% 3/26/2026
Event 3/13/2026

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 218 21.1 M $1.39B
2026 Q2 493 160 M $13.7B
2026 Q1 454 146 M $9.63B
2025 Q4 441 149 M $9.46B
2025 Q3 392 141 M $7.74B
2025 Q2 323 138 M $4.55B
2025 Q1 362 137 M $5.58B
2024 Q4 355 132 M $6.18B
2024 Q3 359 136 M $7.20B
2024 Q2 361 136 M $7.34B
2024 Q1 402 118 M $8.26B
2023 Q4 370 114 M $9.54B
2023 Q3 260 109 M $3.22B
2023 Q2 258 109 M $3.55B
2023 Q1 269 109 M $3.83B
2022 Q4 282 106 M $4.88B
2022 Q3 284 105 M $5.08B
2022 Q2 269 106 M $4.16B
2022 Q1 245 95.5 M $3.52B
2021 Q4 254 91.4 M $4.16B
2021 Q3 216 90.3 M $3.22B
2021 Q2 194 75.6 M $1.50B
2021 Q1 196 74.8 M $1.74B
2020 Q4 185 72.9 M $1.52B
2020 Q3 186 68.8 M $1.49B
2020 Q2 161 57.9 M $1.36B
2020 Q1 150 55.7 M $658M
2019 Q4 142 55.0 M $584M
2019 Q3 150 44.5 M $506M
2019 Q2 135 44.0 M $495M
2019 Q1 139 39.2 M $317M
2018 Q4 138 39.8 M $251M
2018 Q3 125 38.8 M $382M
2018 Q2 127 37.7 M $313M
2018 Q1 127 36.8 M $265M
2017 Q4 134 38.4 M $313M
2017 Q3 133 39.5 M $573M
2017 Q2 137 38.2 M $463M
2017 Q1 109 28.3 M $364M
2016 Q4 101 26.4 M $321M
2016 Q3 92 26.7 M $245M
2016 Q2 96 26.5 M $252M
2016 Q1 109 26.6 M $188M
2015 Q4 126 26.4 M $276M
2015 Q3 105 21.6 M $145M
2015 Q2 97 20.8 M $139M
2015 Q1 93 19.6 M $133M
2014 Q4 84 19.3 M $155M
2014 Q3 85 19.8 M $69.7M
2014 Q2 90 21.0 M $101M
2014 Q1 112 22.5 M $214M